Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Daratumumab plus pomalidomide and dexamethasone (pom-dex) was evaluated in patients with relapsed/refractory multiple myeloma with ≥2 prior lines of therapy who were refractory to their last treatment. Patients received daratumumab 16 mg/kg at the recommended dosing schedule, pomalidomide 4 mg daily...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood
Egile Nagusiak: Chari, Ajai, Suvannasankha, Attaya, Fay, Joseph W., Arnulf, Bertrand, Kaufman, Jonathan L., Ifthikharuddin, Jainulabdeen J., Weiss, Brendan M., Krishnan, Amrita, Lentzsch, Suzanne, Comenzo, Raymond, Wang, Jianping, Nottage, Kerri, Chiu, Christopher, Khokhar, Nushmia Z., Ahmadi, Tahamtan, Lonial, Sagar
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2017
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570682/
https://ncbi.nlm.nih.gov/pubmed/28637662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-05-785246
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak